Skip to main content

Peer Review reports

From: A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

Original Submission
11 Mar 2023 Submitted Original manuscript
8 May 2023 Reviewed Reviewer Report
11 May 2023 Reviewed Reviewer Report
26 May 2023 Reviewed Reviewer Report
6 Jun 2023 Reviewed Reviewer Report
27 Jul 2023 Author responded Author comments - Yaxin Liu
Resubmission - Version 2
27 Jul 2023 Submitted Manuscript version 2
30 Jul 2023 Reviewed Reviewer Report
31 Jul 2023 Reviewed Reviewer Report
16 Aug 2023 Author responded Author comments - Yaxin Liu
Resubmission - Version 3
16 Aug 2023 Submitted Manuscript version 3
22 Aug 2023 Author responded Author comments - Yaxin Liu
Resubmission - Version 4
22 Aug 2023 Submitted Manuscript version 4
Publishing
23 Aug 2023 Editorially accepted
29 Sep 2023 Article published 10.1186/s12916-023-03046-8

You can find further information about peer review here.

Back to article page